Prediabetes Market (2026 - 2033)

Prediabetes Market Summary

The global prediabetes market size was valued at USD 349.0 million in 2025 and is projected to grow from USD 385.0 million in 2026 to USD 730.0 million by 2033, at a CAGR of 9.6% from 2026 to 2033. North America dominated the prediabetes market with the largest revenue share of 41.2% in 2025. The increasing incidence of conditions leading to insulin resistance and impaired glucose metabolism, stemming from mutations in specific genes, serves as the primary driver of the prediabetes industry.

In individuals with prediabetes, blood glucose levels are typically between 100 and 125 mg/dL. According to an article published in the BMC Public Health journal in May 2023, the global prevalence of prediabetes was estimated to be 319 million in 2021 and is projected to increase to 441 by 2045. In addition, the rising prevalence of various associated risk factors, such as sedentary lifestyles, obesity, and unhealthy dietary patterns, contributes significantly to market expansion.

The growing use of antidiabetic medications, especially Metformin, which reduces sugar production and absorption in the body to prevent disease progression, positively impacts market growth. Metformin gained approval from the U.S. FDA in 1994 as a treatment for type 2 diabetes. Available in immediate and extended-release forms, it is frequently combined with other antidiabetic drugs.

Moreover, the rising adoption of continuous glucose monitoring devices, which provide real-time feedback on glucose levels and facilitate disease management, further strengthens market growth. These gadgets prove beneficial in overseeing diabetes among groups like toddlers, pregnant women, the elderly, and those with concurrent health conditions. Furthermore, individuals with prediabetes find value in using continuous glucose monitoring (CGM) technology. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2023, individuals with prediabetes experienced heightened postprandial glucose levels, and the utilization of CGM could trigger behavioral modifications, potentially postponing the onset of diabetes. The increasing adoption of technology for diagnosing prediabetes, in turn, boosts the demand for its treatment.

Market Dynamics

The prediabetes market is witnessing growth due to the rising prevalence of obesity, physical inactivity, and unhealthy dietary habits that increase the risk of developing type 2 diabetes. Growing awareness regarding early diagnosis and disease prevention has encouraged healthcare providers and public health organizations to expand screening and monitoring programs. The market is also benefiting from increasing adoption of lifestyle intervention programs, digital health platforms, and advanced glucose monitoring technologies that support disease management before diabetes onset. Pharmaceutical companies are expanding research efforts focused on therapies that improve glycemic control and weight management among high-risk populations. Demand is further supported by aging populations and increasing healthcare expenditures aimed at reducing the long-term burden of diabetes related complications. However, challenges such as limited patient adherence to lifestyle modifications, underdiagnosis in developing regions, and reimbursement constraints for preventive treatments continue to affect market expansion. Nevertheless, ongoing emphasis on preventive healthcare and early intervention remains a key driver of market development.

Analyst Perspective

The Prediabetes Market is undergoing a shift from traditional diabetes prevention approaches toward integrated metabolic health management that combines pharmacological therapies, lifestyle interventions, and digital health solutions. Established companies are leveraging their expertise in diabetes and obesity care to expand preventive treatment offerings, while emerging players are introducing innovative therapies targeting insulin resistance, gut microbiome modulation, and cardiometabolic risk reduction. Growing awareness of the clinical and economic burden of type 2 diabetes is encouraging earlier intervention among high-risk populations. As evidence supporting weight management and metabolic therapies continues to strengthen, competition is expected to intensify, fostering innovation and broader treatment adoption.

Drug Class Insights

Based on drug class, the diguanide segment led the market with the largest revenue share of 78.4% in 2025 due to its proven efficacy in managing blood glucose levels and improving insulin sensitivity. Metformin is widely recommended as a first-line treatment for prediabetes, as it helps prevent the progression to type 2 diabetes. Its affordability, long track record of safety, and favorable side effect profile have made it a preferred choice among healthcare providers. The increasing awareness of prediabetes and its complications has further fueled the demand for diguanide-based therapies.

The Glucagon-like Peptide-1 Agonists (GLP-1) segment is anticipated to be the fastest-growing segment, with a CAGR of 19.1% from 2025 to 2030, owing to their proven efficacy in improving glycemic control and reducing the risk of progression to type 2 diabetes. These therapies help lower blood sugar levels and promote weight loss, making them highly attractive for prediabetic patients seeking to manage their condition. The increasing global prevalence of prediabetes is expected to drive a surge in demand for GLP-1 agonists, making them a crucial treatment option for early diabetes intervention.

Age Group Insights

Based on age group, the adults (18-49) segment led the market with the largest revenue share of 49.5% in 2025, attributed to increasing awareness of the condition and rising risk factors such as sedentary lifestyles, poor dietary habits, and obesity. This demographic is highly engaged in health monitoring, often seeking preventive care, which makes them more likely to adopt lifestyle changes or medication to manage prediabetes. The digital health platforms and wellness programs tailored to this age group have further fueled growth, as they provide convenient solutions for managing and reversing the condition early, driving prediabetes industry expansion.

The elderly (50+) segment is projected to grow at a significant CAGR from 2025 to 2030 due to increasing life expectancy and rising health concerns among the aging population. The risk of developing prediabetes increases with age, influenced by factors such as sedentary lifestyles, poor diet, and genetic predispositions. This demographic is becoming more proactive about their health, actively seeking early interventions and preventive treatments. Growing awareness of prediabetes and its complications is expected to drive the demand for diagnostic tools, medications, and lifestyle management solutions among the elderly.

Regional Insights

North America dominated the prediabetes market with the largest revenue share of 41.2% in 2025, propelled by the adoption of GLP-1 agonists and the growing interest in personalized treatments. GLP-1 agonists, known for their ability to improve glycemic control and promote weight loss, are increasingly being used to manage prediabetes, offering effective intervention. In addition, personalized medicine, tailored to individual genetic profiles and lifestyle factors, is gaining traction, allowing for more precise and effective treatment plans. These advancements are helping manage prediabetes more efficiently, fueling market growth across the region.

U.S. Prediabetes Market Trends

The prediabetes market in the U.S. held the largest share in the North America region in 2025. The increasing availability of digital health solutions and the rising obesity rates are accelerating the expansion of the prediabetes industry across the U.S. Digital tools such as mobile apps, wearables, and telehealth platforms are making it easier for individuals to monitor their health, track blood sugar levels, and manage lifestyle changes. The rising obesity rate, a major risk factor for prediabetes, prompts more people to seek preventive care. This synergy of increased health technology adoption and the obesity epidemic is anticipated to drive demand for solutions in prediabetes detection, management, and treatment. In November 2023, VALBIOTIS SA announced the success of its product TOTUM•63 in a clinical study evaluating its mode of action for prediabetes treatment. This positive outcome adds to the growing pipeline of pharmacological therapies to improve glucose metabolism, offering a promising new intervention for managing prediabetes in the U.S. market.

Europe Prediabetes Market Trends

Europe prediabetes market is projected to expand at a significant rate over the forecast period. The rising prevalence of prediabetes in Europe, fueled by factors such as the aging population and increasing obesity rates, is expected to fuel the market. The growing diagnosis of prediabetes drives the demand for effective prevention and treatment options. Pharmaceutical advancements, including the development of GLP-1 agonists and other innovative therapies, offer improved blood sugar levels and weight management, enhancing patient outcomes. These advancements, coupled with a focus on early intervention, are set to expand the Europe prediabetes industry in the coming years. In September 2023, Valbiotis and Nestlé Health Science decided to introduce a dietary supplement in 2024 tailored for individuals with prediabetes and type-2 diabetes, following promising outcomes from a study demonstrating the product's effectiveness in improving critical indicators of glucose metabolism.

Asia Pacific Prediabetes Market Trends

Asia Pacific prediabetes market is set to be the fastest-growing region with a CAGR of 11.6% from 2025 to 2030. Rising urbanization and the widespread adoption of a sedentary lifestyle in the region contribute to an increase in prediabetes cases. The shift to desk jobs and increased reliance on processed, high-calorie foods are contributing to the rising prevalence of conditions such as prediabetes. Moreover, genetic predisposition and poor dietary habits, such as high sugar and fat consumption, further exacerbate the situation. The increasing focus on early intervention, along with advancements in treatment options and improved healthcare accessibility, is set to drive significant growth in the Asia Pacific region, with more individuals seeking effective solutions to manage and prevent the condition.

India prediabetes market is anticipated to experience the fastest growth over the forecast period, owing to innovations in diagnostic tools and treatments, coupled with increased health awareness. Advanced technologies, such as more accurate and accessible screening methods, along with improved medications and management strategies, are making early detection and treatment more effective. Furthermore, increasing public awareness about the risks of prediabetes and its potential complications encourages proactive health management. This growing focus on prevention and expanding healthcare access is projected to impel the demand for prediabetes-related solutions in the country.

Key Prediabetes Company Insights

Some of the key companies in the prediabetes industry include Novo Nordisk A/S; Boston Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb Company and Pfizer Inc.

• AstraZeneca provides a broad range of innovative pharmaceutical products, focusing on treatments in oncology, cardiology, nephrology, metabolic diseases, and respiratory conditions. It develops both prescription medications and biologics aimed at improving patient outcomes globally.

• Bristol-Myers Squibb Company offers innovative biopharmaceutical products, focusing on various areas, particularly oncology, immunology, cardiology, and fibrosis. It specializes in developing treatments for serious diseases, including cancer, cardiovascular conditions, and autoimmune disorders.

Competitive Benchmarking

Recent Developments

• In June 2024, Aphaia Pharma announced positive results from its Phase 2 trial of APHD-012, an oral glucose formulation for prediabetes. The trial met its primary endpoint, showing significant improvement in glucose tolerance and a positive safety profile after 6 weeks of treatment.

• In September 2023, Novo Nordisk introduced its “Wegovy” weight loss injection in the UK, providing an innovative treatment option for individuals struggling with obesity. This launch expanded access to effective weight management solutions.

Prediabetes Market Report Scope

Global Prediabetes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global prediabetes market report on the basis of drug class, age group, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Diguanide

  • Thiazolidinediones

  • Glucagon-like peptide-1 agonists (GLP-1)

  • SGLT2 inhibitors

  • DPP-4 inhibitors

  • Others

• Age Group Outlook (Revenue, USD Million, 2021 - 2033)

  • Children (12-18 years)

  • Adults (18-49)

  • Elderly (50+)

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The prediabetes market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each prediabetes segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model 

The prediabetes market size is estimated to use a patient pool and treatment adoption model. The analysis begins with identifying the total population across key countries and regions, followed by estimating the prevalence of prediabetes based on epidemiological studies, public health databases, and diabetes association reports. This helps derive the total prediabetic patient pool. The next step involves determining the diagnosed patient population by evaluating screening rates, healthcare accessibility, and awareness levels. From the diagnosed population, the treated patient pool is calculated by assessing the proportion of individuals enrolled in lifestyle intervention programs, nutritional management plans, glucose monitoring programs, and pharmacological therapies.

Subsequently, the treated patient population is segmented by therapy type, including lifestyle modification programs, anti-diabetic medications prescribed for prediabetes management, digital health solutions, and monitoring services. Market penetration and patient uptake rates for each therapy category are determined through primary interviews with endocrinologists, diabetologists, healthcare providers, and industry experts, supported by secondary research from clinical studies and company publications. Revenue estimation is then performed by multiplying the number of patients receiving each therapy by the average annual cost associated with that therapy. The revenues generated across all treatment categories and regions are aggregated to calculate the overall Prediabetes Market size. Data triangulation, validation through expert interviews, and cross-verification with healthcare expenditure and company revenue data are conducted to ensure the accuracy and reliability of the final market estimates and forecasts.

Delivered Customizations

This report has been delivered with the following In-depth customizations